Home
Search:
1146 feeds
357 categories
3590 articles (<24 hours)
27 registered users

Use the Mobile version
Mobile

Follow our Twitter feed

View our Linkpartners
Links

Username:
Password:

Register | Retrieve

General


RSS FeedsGilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)
(WorldNews Switzerland)

 
 

4 july 2020 13:28:22

 
Gilead Sciences Presents Data Supporting a Potential Six-Month Dosing Interval for Investigational HIV-1 Capsid Inhibitor Lenacapavir (GS-6207)
(WorldNews Switzerland)
 


FOSTER CITY, Calif.--(BUSINESS WIRE)-- Gilead Sciences, Inc. (Nasdaq: GILD) today announced data from an ongoing Phase 1 study, which showed that a sustained-delivery subcutaneous formulation of the company`s investigational, novel inhibitor of HIV-1 capsid function, lenacapavir (GS-6207), sustained predicted therapeutic concentrations for at least six months following a single 900 mg dose. In the study, lenacapavir was generally well-tolerated, and no serious adverse events were reported. These data were presented at the 23rd International AIDS Conference (AIDS 2020: Virtual). `Long-acting antiretroviral therapy may help address challenges with treatment adherence and treatment fatigue,...


 
61 viewsCategory: General > Europe > Switzerland
 
Two Trains Collided in a Mountain Tunnel in Switzerland
(WorldNews Switzerland)
FIA Formula One Grosser Preis von Österreich 2020 – Qualifying – Saturday
(WorldNews Switzerland)
 
 
blog comments powered by Disqus


Copyright © 2008 - 2020 Indigonet Services B.V.. Contact: Tim Hulsen. Read here our privacy notice.
Other websites of Indigonet Services B.V.: Nieuws Vacatures Science Tweets Nachrichten